Avadel PharmaceuticalsAVDL
About: Avadel Pharmaceuticals PLC is a specialty pharmaceutical company. It identifies, develops, and commercializes branded pharmaceutical products including controlled-release therapeutic products based on its proprietary drug delivery technologies in the United States. The company is engaged in development of differentiated drug products for administration in various forms such as capsules, tablets, injectables etc. Its commercialized product LUMRYZ is an extended-release formulation of sodium oxybate indicated to be taken once at bedtime for the treatment of cataplexy or EDS in adults with narcolepsy.
Employees: 154
Fund manager confidence
Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)
188% more call options, than puts
Call options by funds: $31.3M | Put options by funds: $10.9M
123% more first-time investments, than exits
New positions opened: 49 | Existing positions closed: 22
21% more funds holding
Funds holding: 126 [Q1] → 153 (+27) [Q2]
13% more repeat investments, than reductions
Existing positions increased: 43 | Existing positions reduced: 38
12% more capital invested
Capital invested by funds: $1.22B [Q1] → $1.37B (+$151M) [Q2]
2.01% less ownership
Funds ownership: 79.6% [Q1] → 77.59% (-2.01%) [Q2]
20% less funds holding in top 10
Funds holding in top 10: 10 [Q1] → 8 (-2) [Q2]
Research analyst outlook
9 Wall Street Analysts provided 1 year price targets over the past 3 months
9 analyst ratings
Needham Ami Fadia 66% 1-year accuracy 96 / 146 met price target | 67%upside $22 | Buy Reiterated | 12 Nov 2024 |
HC Wainwright & Co. Oren Livnat 55% 1-year accuracy 22 / 40 met price target | 105%upside $27 | Buy Reiterated | 31 Oct 2024 |
Oppenheimer Francois Brisebois 71% 1-year accuracy 24 / 34 met price target | 128%upside $30 | Outperform Maintained | 31 Oct 2024 |
Needham Ami Fadia 66% 1-year accuracy 96 / 146 met price target | 67%upside $22 | Buy Reiterated | 31 Oct 2024 |
HC Wainwright & Co. Oren Livnat 55% 1-year accuracy 22 / 40 met price target | 105%upside $27 | Buy Reiterated | 21 Oct 2024 |
Financial journalist opinion
Based on 5 articles about AVDL published over the past 30 days